
Gilead Sciences GILD
$ 130.5
-0.15%
Quarterly report 2026-Q1
added 05-07-2026
Gilead Sciences DPO Ratio 2011-2026 | GILD
Annual DPO Ratio Gilead Sciences
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 45.3 | 40.4 | 40.9 | 51.9 | 42.8 | 62.2 | 55.7 | 59.4 | 68 | 103 | 107 | 92 | 160 | 196 | 207 | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 207 | 40.4 | 88.9 |
Quarterly DPO Ratio Gilead Sciences
| 2026-Q1 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | 2010-Q3 | 2010-Q2 | 2010-Q1 | 2009-Q3 | 2009-Q2 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 45.9 | 40.4 | 40.1 | 46.5 | - | 41.7 | 34.2 | 34.5 | - | 35.2 | 39.5 | 49.9 | - | 38.6 | 36.3 | 41.3 | - | 44.5 | 38.7 | 47.4 | - | 67.5 | 72.4 | 73.3 | - | 62.9 | 65.1 | 71.7 | - | 66.4 | 60.3 | 73.1 | - | 72 | 66 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 73.3 | 34.2 | 52 |
DPO Ratio of other stocks in the Biotechnology industry
| Issuer | DPO Ratio | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Happiness Biotech Group Limited
HAPP
|
5.06 K | - | 1.35 % | $ 17.8 M | ||
|
AgeX Therapeutics
AGE
|
5.24 K | - | -10.17 % | $ 12.2 K | ||
|
I-Mab
IMAB
|
2.24 K | - | - | $ 866 M | ||
|
Alexion Pharmaceuticals, Inc.
ALXN
|
78.2 | - | - | $ 40.3 B | ||
|
AstraZeneca PLC
AZN
|
265 | - | - | $ 96.9 B | ||
|
Midatech Pharma plc
MTP
|
162 | - | -18.52 % | $ 27.3 M | ||
|
Esperion Therapeutics
ESPR
|
7.93 K | $ 3.13 | - | $ 651 M | ||
|
Eton Pharmaceuticals
ETON
|
74.3 | $ 35.0 | 1.6 % | $ 942 M | ||
|
Институт стволовых клеток человека
ISKJ
|
115 | - | - | - | ||
|
Celyad Oncology SA
CYAD
|
55.8 K | - | - | $ 12.5 M | ||
|
Berkeley Lights
BLI
|
135 | - | -7.31 % | $ 87 M | ||
|
Autolus Therapeutics plc
AUTL
|
9.57 | $ 1.65 | 1.85 % | $ 439 M | ||
|
Ayala Pharmaceuticals
AYLA
|
2.21 K | - | - | $ 7.46 M | ||
|
Cyclacel Pharmaceuticals
CYCCP
|
1.79 K | - | -4.36 % | $ 27 M | ||
|
Heron Therapeutics
HRTX
|
91.4 | $ 0.87 | 3.09 % | $ 145 M | ||
|
Compugen Ltd.
CGEN
|
82.7 | $ 2.61 | -3.51 % | $ 244 M | ||
|
Anika Therapeutics
ANIK
|
43.4 | $ 15.02 | -0.79 % | $ 215 M | ||
|
Advaxis
ADXS
|
85.6 K | - | -9.65 % | $ 45.9 M | ||
|
Aeterna Zentaris
AEZS
|
34.4 K | - | 5.93 % | $ 314 M | ||
|
Incyte Corporation
INCY
|
200 | $ 97.41 | 0.34 % | $ 19 B | ||
|
Ionis Pharmaceuticals
IONS
|
815 | $ 75.78 | 0.96 % | $ 12.1 B | ||
|
AIkido Pharma
AIKI
|
1.92 | - | 1.93 % | $ 17.4 M | ||
|
Coherus BioSciences
CHRS
|
507 | $ 1.57 | 3.97 % | $ 184 M | ||
|
Albireo Pharma
ALBO
|
1.59 K | - | -0.23 % | $ 916 M | ||
|
Arcutis Biotherapeutics
ARQT
|
133 | $ 21.01 | 2.64 % | $ 2.67 B |